Goldenseal

Goldenseal alkaloids berberine and (-)-β-hydrastine cause time-dependent (mechanism-based) inhibition of CYP3A4 in vivo. A clinical study using midazolam as a phenotypic probe demonstrated approximately 40% reduction in CYP3A4/5 activity following 14 days of goldenseal supplementation (~1 g TID). Hydrastine is a potent mechanism-based CYP3A4 inhibitor (KI = 28 µM, kinact = 0.056 min⁻¹). This results in reduced first-pass and hepatic metabolism of CYP3A4 substrates, increasing their plasma levels and risk of toxicity.

Avoid concurrent use of goldenseal with narrow therapeutic index CYP3A4 substrates (cyclosporine, tacrolimus, simvastatin). For other CYP3A4 substrates, monitor for signs of drug toxicity and consider dose reduction. Effects persist for days after goldenseal discontinuation due to mechanism-based enzyme inactivation. Allow at least 2 weeks washout before initiating sensitive CYP3A4 substrates.

Goldenseal extract strongly inhibits CYP2D6 activity in vivo (approximately 40-60% reduction in debrisoquin/dextromethorphan metabolic ratios). Berberine is a time-dependent CYP2D6 inhibitor (KI = 2.7 µM, kinact = 0.065 min⁻¹). This results in elevated plasma concentrations of CYP2D6-dependent drugs, converting extensive metabolisers to a phenocopy of poor metaboliser status and increasing risk of adverse effects or toxicity.

Avoid goldenseal with narrow therapeutic index CYP2D6 substrates (e.g., codeine — loss of conversion to morphine may reduce analgesia; haloperidol, metoprolol — elevated plasma levels cause toxicity). Monitor closely if co-administration is unavoidable. Clinical significance is equivalent to a strong CYP2D6 inhibitor drug such as fluoxetine.

(-)-β-Hydrastine, a major alkaloid of goldenseal, is a mechanism-based inhibitor of CYP2C9 (KI = 49 µM, kinact = 0.036 min⁻¹), which is the primary enzyme responsible for S-warfarin hydroxylation. Inhibition of S-warfarin metabolism increases plasma warfarin levels and anticoagulant effect. Berberine also modestly inhibits CYP2C9 in vitro. Additionally, berberine has some intrinsic antiplatelet activity that may further potentiate bleeding risk.

Monitor INR closely if goldenseal is initiated or discontinued in warfarin-treated patients. Dose adjustment of warfarin may be necessary. Given the mechanism-based nature of the CYP2C9 inhibition, effects may persist for days after goldenseal discontinuation. Avoid combination where possible in patients with unstable INR.

Berberine (a primary alkaloid in goldenseal) inhibits CYP3A4-mediated cyclosporine clearance. A randomised clinical study in 104 renal transplant recipients showed that berberine 200 mg TID for 12 days increased cyclosporine AUC by 34.5%. Combined CYP3A4 and P-glycoprotein inhibition by goldenseal alkaloids substantially reduces cyclosporine elimination, increasing the risk of nephrotoxicity and other calcineurin inhibitor toxicities.

Contraindicated in transplant patients on cyclosporine. Even at standard goldenseal supplement doses, the CYP3A4 inhibition is clinically significant. Monitor cyclosporine blood levels immediately if exposure has occurred. Tacrolimus interactions should be assumed equivalent given shared CYP3A4/P-gp metabolism.

A clinical pharmacokinetic study showed that goldenseal supplementation (3,210 mg/day for 14 days) did NOT significantly alter digoxin pharmacokinetics, suggesting goldenseal does not meaningfully inhibit P-glycoprotein (ABCB1) in vivo at standard doses. However, the pharmacodynamic effects of berberine on cardiac conduction (QT prolongation, negative chronotropy) warrant caution in patients taking digoxin, as additive effects on heart rate and cardiac rhythm are theoretically possible.

Clinical pharmacokinetic interaction with digoxin is unlikely based on current evidence. Monitor for additive effects on heart rate and cardiac conduction. Check ECG if patient develops bradycardia or arrhythmia while using both agents. No dose adjustment of digoxin is required based on available data.

Berberine, a principal alkaloid of goldenseal, has clinically demonstrated glucose-lowering effects mediated through AMPK activation, improved insulin sensitivity, and inhibition of intestinal glucose absorption. A randomised clinical trial in 116 type-2 diabetic patients showed berberine (500 mg TID for 3 months) reduced HbA1c by 2.0% and fasting glucose by 3.0 mmol/L, comparable to metformin. Additive hypoglycaemic effects when combined with antidiabetic medications can cause clinically significant hypoglycaemia.

Monitor blood glucose closely when initiating or discontinuing goldenseal in patients on antidiabetic medications. Dose adjustments of antidiabetic agents may be required. Patients should be educated on signs of hypoglycaemia. Particularly relevant in patients on insulin or sulfonylureas, where hypoglycaemia risk is highest.

Goldenseal strongly inhibits intestinal and hepatic CYP3A4, the primary metabolic pathway for most HIV protease inhibitors. A clinical study showed goldenseal root significantly altered indinavir pharmacokinetics via CYP3A4 inhibition. Elevated antiretroviral plasma levels may cause toxicity (nephrotoxicity with indinavir, QT prolongation with others) or complicate virologic management.

Avoid concurrent use of goldenseal with HIV protease inhibitors or NNRTIs metabolized by CYP3A4. If use is unavoidable, consult an HIV specialist for dose adjustment and closely monitor for antiretroviral toxicity. Do not self-initiate or discontinue goldenseal during active HIV treatment.

Berberine, the primary alkaloid in goldenseal, has independent antihypertensive effects through vasodilation via endothelial nitric oxide upregulation and modulation of adrenergic tone. Co-administration with prescription antihypertensive drugs may produce additive blood pressure reduction, potentially causing symptomatic hypotension, particularly in elderly patients or those on combination antihypertensive regimens.

Monitor blood pressure when combining goldenseal with antihypertensive medications. Dose adjustment of the antihypertensive drug may be necessary. Advise patients to report symptoms of dizziness, lightheadedness, or syncope. Caution in patients on multiple antihypertensive agents.

Apixaban and rivaroxaban are CYP3A4 and P-glycoprotein substrates. Goldenseals well-documented CYP3A4 inhibition (clinical studies showed ~40-60% increase in midazolam AUC at 3g/day) can increase DOAC plasma concentrations, significantly elevating bleeding risk. Unlike warfarin, DOACs have no standard therapeutic monitoring test analogous to INR, making toxicity harder to detect.

Avoid concurrent use of goldenseal with DOACs. If a patient initiates goldenseal while on a DOAC, inform the prescribing clinician immediately. Monitor for signs of bleeding (bruising, haematuria, melaena). Dose adjustment of the DOAC may be required; consider switching to renal-cleared agents less reliant on CYP3A4.